{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:28:31Z","timestamp":1761964111890,"version":"build-2065373602"},"reference-count":48,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1892,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p>Uncontrolled diabetes mellitus is associated with both microvascular and macrovascular complications. Despite an array of treatment options available, achievement of euglycemia in most patients with diabetes is still lacking. Pramlintide acetate, a synthetic analog of the human hormone amylin and belonging to a new class of agents, was approved in March 2005 as adjunctive treatment in patients with type 1 or 2 diabetes mellitus. To evaluate the data available on the efficacy and safety of pramlintide, we conducted a search of MEDLINE (January 1966\u2013May 2006) and International Pharmaceutical Abstracts (January 1970\u2013May 2006). Bibliographies of clinical trials were reviewed for additional references. The literature reviewed demonstrated that pramlintide is effective in reducing levels of glycosylated hemoglobin and potentially preventing weight gain. The most commonly reported adverse effects associated with pramlintide were nausea, anorexia, and hypoglycemia. These adverse effects occurred more often during the initiation of therapy and were usually mild to moderate in nature. Whether this therapy is a cost\u2010effective option for patients with type 1 or type 2 diabetes mellitus is yet to be determined.<\/jats:p>","DOI":"10.1592\/phco.26.11.1626","type":"journal-article","created":{"date-parts":[[2006,10,27]],"date-time":"2006-10-27T13:17:55Z","timestamp":1161955075000},"page":"1626-1640","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adjunctive Therapy with Pramlintide in Patients with Type 1 or Type 2 Diabetes Mellitus"],"prefix":"10.1002","volume":"26","author":[{"given":"Anna","family":"Nogid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Q.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"American Diabetes Association.Statistics. Available fromhttp:www.diabetes.orguedocumentsNationalDiabetesFactSheetRev.pdf. Accessed May 25 2006."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397357"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp021106"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.s1.06.s43"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306103282306"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes","volume":"352","author":"The United Kingdom Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.29.s1.06.s4","article-title":"Standard of medical care in diabetes, 2006","volume":"29","author":"American Diabetes Association","year":"2006","journal-title":"Diabetes Care"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.7.744"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150260007390"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90785-2"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.8.2822"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)90388-3"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.2.7378"},{"issue":"2","key":"e_1_2_1_16_2","first-page":"S10","article-title":"Effects of amylin and the amylin agonist pramlintide on glucose metabolism","volume":"14","author":"Schmitz O.","year":"1997","journal-title":"Diabet Med"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0026-895X(25)13212-4","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont K.","year":"1993","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2002.00311.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050646"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1152\/ajpgi.2000.278.6.G946","article-title":"Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition","volume":"278","author":"Samson M.","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200194080-00011"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/014572179902500310"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464130-00003"},{"issue":"2","key":"e_1_2_1_25_2","first-page":"235A","article-title":"The selection of pramlintide for clinical evaluation [abstr]","volume":"45","author":"Janes S.","year":"1996","journal-title":"Diabetes"},{"volume-title":"Symlin (pramlintide acetate) injection package insert","year":"2005","author":"Amylin Pharmaceuticals, Inc.","key":"e_1_2_1_26_2"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04147.x"},{"key":"e_1_2_1_28_2","unstructured":"Amylin Pharmaceuticals Inc.Symlin (pramlintide acetate) injection (NDA no. 21\u2013332) advisory committee briefing document. Available fromhttp:www.fda.govohrmsdocketsac01briefing3761b1_01_Amylin.pdf. Accessed January 26 2006."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-837662"},{"issue":"1","key":"e_1_2_1_32_2","first-page":"A113","article-title":"Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes [abstr]","volume":"48","author":"Fineman M.","year":"1999","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_1_33_2","first-page":"A109","article-title":"Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks [abstr]","volume":"49","author":"Gottlieb A.","year":"2000","journal-title":"Diabetes"},{"key":"e_1_2_1_34_2","unstructured":"Guthrie R. Karl D.M. Lorenzi G..In an open\u2010label clinical study pramlintide lowered A1C body weight and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy. Presented at the 65th annual scientific sessions of the American Diabetes Association San Diego CA June 1014 2005."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150252924094"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00295.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.76"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2003.06.003"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.6.987"},{"issue":"1","key":"e_1_2_1_41_2","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 months [abstr]","volume":"42","author":"Gottlieb A.","year":"1999","journal-title":"Diabetogia"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6925.367"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.10.946"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C387"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050341"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00417.x"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","unstructured":"Weyer C. Wang Y. Schnabel C. Kolterman O..Pramlintide pharmacokinetics in type 1 and type 2 diabetes: effects of injection site needle length and body size. Presented at the 64th annual scientific sessions of the American Diabetes Association Orlando FL June 48 2004.","DOI":"10.1016\/S1530-891X(20)46398-0"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.8.816"},{"key":"e_1_2_1_49_2","unstructured":"Prescription Solutions.Symlin (pramlintide acetate) injections. RxNews. FDA update. 3\/31\/05: new drug approval notification. Available fromhttp:www.rxsolutions.comcrxnewsrxnews_view.aspArticle568&type18. Accessed May 26 2006."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.11.1626","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.11.1626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:30:51Z","timestamp":1761042651000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.11.1626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1592\/phco.26.11.1626"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.11.1626","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}